TGFB1 and glioblastoma: As myeloid cells are ubiquitously present in the body, we here used a vector with MMP14 promoter17 to deliver TGFβ-blocking therapy specifically to experimental brain tumors, and thereby provided a proof-of-principle for the efficacy of HSC gene therapy targeting GBM using a tumor myeloid cell-specific gene promoter.